Vaccination therapy for non-small-cell lung cancer
Recent advances in our understanding of cancer immunology resulted in the development of promising therapeutic agents for either nonantigen-specific immunotherapy, for example, monoclonal antibodies targeting immune checkpoints on the T-cell lymphocyte, and antigen-specific immunotherapy or vaccination. Here, we review the recently reported results from randomized controlled trials (RCTs) with the latter approach.status: publishe
Cancer Vaccines, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Randomized Controlled Trials as Topic, Survival Analysis, Treatment Outcome, Vaccination
Publisher: 'Ovid Technologies (Wolters Kluwer Health)'
DOI identifier: 10.1097/CCO.0000000000000052
Sorry, we are unable to provide the full text but you may find it at the